Skip to main content
Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs

Fig. 2

Patients reporting improvements ≥ MCID at week 12 across PROs. a Results from multiple patient health-related quality of life assessments. b Results from the SF-36 subdomains. SF-36 domains were rescored from 0 to 100, where 0 is the worst and 100 is the best. No further transformations were applied. *P < 0.05 for UPA vs PBO. AM, morning; BP, bodily pain; EQ-5D-5L, Euro Qol 5-Dimension 5-Level Questionnaire; GH, general health; HAQ-DI, Health Assessment Questionnaire Disability Index; ISI, Insomnia Severity Index; MCID, minimum clinically important difference; MCS, Mental Component Summary; MH, mental health; NNT, number needed to treat; PBO, placebo; PCS, Physical Component Summary; PF, physical functioning; PRO, patient-reported outcome; PtGA, Patient Global Assessment of Disease Activity; RE, role-emotional; RP, role-physical; SF, social functioning; SF-36, Short Form-36 Health Survey; UPA, upadacitinib; VAS, visual analog scale; VT, vitality

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us